Observations placeholder
Dantrium
Identifier
018843
Type of Spiritual Experience
Background
A description of the experience
Dantrolene sodium is a postsynaptic muscle relaxant that lessens excitation-contraction coupling in muscle cells. It achieves this by inhibiting Ca2+ ions release from sarcoplasmic reticulum stores by antagonizing ryanodine receptors. It is the primary drug used for the treatment and prevention of malignant hyperthermia, a life-threatening disorder triggered by general anesthesia.
It is also used in the management of neuroleptic malignant syndrome, muscle spasticity (e.g. after strokes, in paraplegia, cerebral palsy, or patients with multiple sclerosis), and 2,4-dinitrophenol poisoning. It is marketed as Dantrium (in North America) and as Dantrium, Dantamacrin, or Dantrolen (in Europe).
On Nov, 19, 2015: 934 people reported to have side effects when taking Dantrium. Among them, 3 people (0.32%) have Hallucination.
On Nov, 11, 2015: 342 people reported to have side effects when taking Dantrolene sodium. Among them, 4 people (1.17%) have Hallucination.
On Nov, 22, 2015: 934 people reported to have side effects when taking Dantrium. Among them, 4 people (0.43%) have Death.
On Dec, 1, 2015: 342 people reported to have side effects when taking Dantrolene sodium. Among them, 4 people (1.17%) have Death.
Time on Dantrolene sodium when people have Death :
< 1 month1 - 6 months6 - 12 months1 - 2 years2 - 5 years5 - 10 years10+ years Death50.00%50.00%0.00%0.00%0.00%0.00%0.00%